Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Disorders of Sex Development 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × STA 9090 × Clear all
NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡